Low-stage medulloblastoma: Final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation

Patrick R.M. Thomas, Melvin Deutsch, James L. Kepner, James M. Boyett, Jeffrey Krischer, Patricia Aronin, Leland Albright, Jeffrey C. Allen, Roger J. Packer, Rita Linggood, Raymond Mulhern, James A. Stehbens, James Langston, Philip Stanley, Patricia Duffner, Lucy Rorke, Joel Cherlow, Henry S. Friedman, Jonathan L. Finlay, Teresa J. ViettiLarry E. Kun

Research output: Contribution to journalArticle

224 Scopus citations

Abstract

Purpose: To evaluate prospectively the effects on survival, relapse-free survival, and patterns of relapse of reduced-dose (23.4 Gy in 13 fractions) compared with standard-dose (36 Gy in 20 fractions) neuraxis irradiation in patients 3 to 21 years of age with low-stage medulloblastoma, minimal postoperative residual disease, and no evidence of neuraxis disease. Patients and Methods: The Pediatric Oncology Group and Children's Cancer Group randomized 126 patients to the study. All patients received posterior fossa irradiation to a total dose of 54 Gy in addition to the neuraxis treatment. Patients were staged postoperatively with contrast-enhanced cranial computed to mography, myelography, and CSF cytology. Of the registered patients, 38 were ineligible. Results: The planned interim analysis that resulted in closure of the protocol showed that patients randomized to the reduced neuraxis treatment had increased frequency of relapse. In the final analysis, eligible patients receiving standard-dose neuroxis irradiation had 67% event-free survival (EFS) at 5 years (SE = 7.4%), whereas eligible patients receiving reduced-dose neuroxis irradiation had 52% event-free survival at 5 years (SE = 7.7%) (P = .080). At 8 years, the respective EFS proportions were also 67% (SE = 8.8%) and 52% (SE = 11%) (P = .141). These data confirm the original one-sided conclusions but suggest that differences are less marked with time. Conclusion: Reduced-dose neuroxis irradiation (23.4 Gy) is associated with increased risk of early relapse, early isolated neuraxis relapse, and lower 5-year EFS and overall survival than standard irradiation (36 Gy). The 5-year EFS for patients receiving standard-dose irradiation is suboptimal, and improved techniques and/or therapies are needed to improve ultimate outcome. Chemotherapy may contribute to this improvement. (C) 2000 by American Society of Clinical Oncology.

Original languageEnglish (US)
Pages (from-to)3004-3011
Number of pages8
JournalJournal of Clinical Oncology
Volume18
Issue number16
DOIs
StatePublished - Jan 1 2000

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Low-stage medulloblastoma: Final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation'. Together they form a unique fingerprint.

  • Cite this

    Thomas, P. R. M., Deutsch, M., Kepner, J. L., Boyett, J. M., Krischer, J., Aronin, P., Albright, L., Allen, J. C., Packer, R. J., Linggood, R., Mulhern, R., Stehbens, J. A., Langston, J., Stanley, P., Duffner, P., Rorke, L., Cherlow, J., Friedman, H. S., Finlay, J. L., ... Kun, L. E. (2000). Low-stage medulloblastoma: Final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. Journal of Clinical Oncology, 18(16), 3004-3011. https://doi.org/10.1200/JCO.2000.18.16.3004